Efficacy and Safety of a Novel Thrombectomy Device in Patients With Acute Ischemic Stroke: A Randomized Controlled Trial

Zhang, Yongxin; Hua, Weilong; Li, Zifu; Peng, Ya; Han, Zenghui; Li, Tong; Chen, Yin; Wang, Shoucun; Guo, Nan; Zhao, Zhenwei; Yang, Hua; Zhou, Bin; Li, Tianxiao; Cai, Yuyang; Zhang, Jianmin; Li, Guifu; Peng, Xiaoxiang; Guan, Sheng; Zhou, Junshan; Ye, Ming; Wang, Liqin; Zhang, Lei; Hong, Bo; Zhang, Yong‐Wei; Wan, Jieqing; Wang, Yang; Zhu, Qiyu; Liu, Jianmin; Yang, Pengfei

doi:10.3389/fneur.2021.686253

Cited by 5 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 It has been reported that ischemic stroke (IS) constitutes about 85% of all stroke patients. 4 Even though many efforts are being put into developing new strategies to treat ischemic stroke, the only effective treatment for stroke is intravascular thrombolysis or thrombectomy. 5 Thus, to identify novel therapies seems curial, and further to reveal the mechanism of the pathological progress in stroke would provide efforts to develop the new treatment.…”

Section: Introductionmentioning

confidence: 99%

LncRNA FTX Regulates Angiogenesis Through miR-342-3p/SPI1 Axis in Stroke

Gao¹,

Wang²

2021

NDT

View full text Add to dashboard Cite

Background Long non-coding RNAs (lnc-RNAs) and microRNAs (miRNAs) play key roles in the development of stroke. However, the role of lncRNA FTX in stroke is limited known. Methods Real-time polymerase chain reaction (real-time PCR) assays were used to measure the expression of lncRNA FTX, miR-342-3p and SPI1. Western blot assays were employed to examine SPI1 protein expression. The cell viability was measured by CCk8 assay. Cell migration was detected by wound healing assays and transwell assays. Angiogenesis was evaluated by matrigel tube formation assays. The interaction between lncRNA FTX, miR-342-3p and SPI1 was confirmed by site-directed mutagenesis and luciferase assays. Results The expression of lncRNA FTX was down-regulated in blood sample from stroke patients, MAO mice tissues and OGD/R treated BMECs. Overexpression of lncRNA FTX could increase the cell viability, migration and angiogenesis in OGD/R treated BMECs. LncRNA FTX could act as a ceRNA for miR-342-3p. Furthermore, miR-342-3p inhibition increased migration and angiogenesis in OGD/R-induced BMECs. Dual-luciferase reporter assay verified that SPI1 was a target of miR-342-3p. Conclusion In summary, lncRNA FTX enhanced the angiogenesis in stroke by acting as a sponge of miR-342-3p to regulate the expression of SPI1 level.

show abstract

Section: Introductionmentioning

confidence: 99%

LncRNA FTX Regulates Angiogenesis Through miR-342-3p/SPI1 Axis in Stroke

Gao¹,

Wang²

2021

NDT

View full text Add to dashboard Cite

show abstract

“…A randomized clinical trial found no significant difference in infarct size between NBP and placebo groups in humans, although the NBP group exhibited better functional outcomes after 90 days poststroke. 21 Oral NBP treatment starting at 2 hours and for 3 weeks after ischemia/reperfusion also did not reduce infarct size in rhesus monkeys, although a trend of decreased infarct size was observed in the NBP group. 26 In our study, NBP starting at 6 hours and for 12 weeks also did not decrease infarct size at 4 weeks after permanent MCAO in cynomolgus monkeys, although it significantly improved WM.…”

Section: Discussionmentioning

confidence: 82%

“…The dosing regimen of NBP was established based on the standard clinical administration, involving a 14-day intravenous administration of 50 mg/day, followed by an oral regimen of 600 mg/day from day 15 to 90. 21 To adapt this dosage for use in cynomolgus monkeys, we used a dose translation method as follows: 22…”

Section: Methodsmentioning

confidence: 99%

Dl-3-n-Butylphthalide Alleviates Secondary Brain Damage and Improves Working Memory After Stroke in Cynomolgus Monkeys

Jiang,

Wei,

Liang

et al. 2024

Stroke

View full text Add to dashboard Cite

BACKGROUND: Remote secondary neurodegeneration is associated with poststroke cognitive impairment (PSCI). Dl-3-n-butylphthalide (NBP) improves PSCI clinically. However, whether it ameliorates PSCI by alleviating secondary neurodegeneration remains uncertain. Nonhuman primates provide more relevant models than rodents for human stroke and PSCI. This study investigated the effects of NBP on PSCI and secondary neurodegeneration in cynomolgus monkeys after permanent left middle cerebral artery occlusion (MCAO). METHODS: Thirteen adult male cynomolgus monkeys were randomly assigned to sham (n=4), MCAO+placebo (n=5), and MCAO+NBP groups (n=4). The MCAO+placebo and MCAO+NBP groups received saline and NBP injections intravenously, respectively, starting at 6-hour postsurgery for 2 weeks, followed by soybean oil and NBP orally, respectively, for 10 weeks after MCAO. Infarct size was assessed at week 4 by magnetic resonance imaging. Working memory and executive function were evaluated dynamically using the delayed response task and object retrieval detour task, respectively. Neuron loss, glia proliferation, and neuroinflammation in the ipsilateral dorsal lateral prefrontal cortex, thalamus, and hippocampus were analyzed by immunostaining 12 weeks after MCAO. RESULTS: Infarcts were located in the left middle cerebral artery region, apart from the ipsilateral dorsal lateral prefrontal cortex, thalamus, or hippocampus, with no significant difference between the MCAO+placebo and MCAO+NBP group. Higher success in delayed response task was achieved at weeks 4, 8, and 12 after NBP compared with placebo treatments ( P <0.05), but not in the object retrieval detour task (all P >0.05). More neurons and less microglia, astrocytes, CD68-positive microglia, tumor necrosis factor-α, and inducible NO synthase were observed in the ipsilateral dorsal lateral prefrontal cortex and thalamus after 12 weeks of NBP treatment ( P <0.05), but not in the hippocampus ( P >0.05). CONCLUSIONS: Our findings indicate that NBP improves working memory by alleviating remote secondary neurodegeneration and neuroinflammation in the ipsilateral dorsal lateral prefrontal cortex and thalamus after MCAO in cynomolgus monkeys.

show abstract

“…The Tonbridge stent (Tonbridge Medical Technology, Guangzhou, China) was compared to the Solitaire stent-retriever in 208 patients with AIS due to LVO within 6 hours of symptom onset. The Tonbridge device showed non-inferiority, with similar rates of all-cause mortality and 90-day mRS of 0-2 [ 22 ].…”

Section: Reviewmentioning

confidence: 99%

Randomized Clinical Trials in Cerebrovascular Neurosurgery From 2018 to 2022

Kappel,

Nguyen,

Frerichs

et al. 2024

Cureus

View full text Add to dashboard Cite

There has been an exponential increase in randomized controlled trials (RCTs) on cerebrovascular disease within neurosurgery. The goal of this study was to review, outline the scope, and summarize all phase 2b and phase 3 RCTs impacting cerebrovascular neurosurgery practice since 2018. We searched PubMed, MEDLINE, Embase, ClinicalTrials.gov , and the Cochrane Central Register of Controlled Trials (CENTRAL) databases for relevant RCTs published between January 1, 2018, and July 1, 2022. We searched for studies related to eight major cerebrovascular disorders relevant to neurosurgery, including acute ischemic stroke, cerebral aneurysms and subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematomas, cerebral venous thrombosis, arteriovenous malformations, Moyamoya disease and extracranial-intracranial bypass, and carotid and intracranial atherosclerosis. We limited our search to phase 2b or 3 RCTs related to cerebrovascular disorders published during the study period. The titles and abstracts of all relevant studies meeting our search criteria were included. Pediatric studies, stroke studies related to rehabilitation or cardiovascular disease, study protocols without published results, prospective cohort studies, registry studies, cluster randomized trials, and nonrandomized pivotal trials were excluded. From an initial total of 2,797 records retrieved from the database searches, 1,641 records were screened after duplicates and studies outside of our time period were removed. After screening, 511 available reports within our time period of interest were assessed for eligibility. Pediatric studies, stroke studies related to rehabilitation or cardiovascular disease, study protocols without published results, prospective cohort studies, registry studies, cluster randomized trials, and nonrandomized pivotal trials were excluded. We found 80 unique phase 2b or 3 RCTs that fit our criteria, with 165 topic-relevant articles published within the study period. Numerous RCTs in cerebrovascular neurosurgery have been published since 2018. Ischemic stroke, including mechanical thrombectomy and thrombolysis, accounted for a majority of publications, but there were large trials in intracerebral hemorrhage, subdural hemorrhage, aneurysms, subarachnoid hemorrhage, and cerebral venous thrombosis, among others. This review helps define the scope of the large RCTs published in the last four years to guide future research and clinical care.

show abstract

Efficacy and Safety of a Novel Thrombectomy Device in Patients With Acute Ischemic Stroke: A Randomized Controlled Trial

Cited by 5 publications

References 36 publications

LncRNA FTX Regulates Angiogenesis Through miR-342-3p/SPI1 Axis in Stroke

LncRNA FTX Regulates Angiogenesis Through miR-342-3p/SPI1 Axis in Stroke

Dl-3-n-Butylphthalide Alleviates Secondary Brain Damage and Improves Working Memory After Stroke in Cynomolgus Monkeys

Randomized Clinical Trials in Cerebrovascular Neurosurgery From 2018 to 2022

Contact Info

Product

Resources

About